Premium
Real‐world experience of off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
Author(s) -
Lallas A.,
Moscarella E.,
Kittler H.,
Longo C.,
Thomas L.,
Zalaudek I.,
Kyrgidis A.,
Manoli S.M.,
Meo N.,
Papageorgiou C.,
Apalla Z.,
Argenziano G.
Publication year - 2021
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.20407
Subject(s) - imiquimod , lentigo maligna , medicine , dermatology , adjuvant therapy , adjuvant , surgery , general surgery , oncology , melanoma , chemotherapy , cancer research
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom